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Cytophagic and S-100 protein
immunoreactive myeloid
leukemia cutis
Myeloid leukemia cutis (LC) is the cutaneous involvement by
neoplastic leukocytes of the myeloid series. Myeloid LC may occur de
novo or concurrently with acute myeloid leukemias, chronic myeloid
leukemias, other myeloproliferative disorders or myelodysplastic
syndromes. We describe an unusual case of cytophagic S-100 protein
immunoreactive leukemia cutis presenting in an 87-year-old woman
without prior history of myeloid leukemia or other hematologic
disorders. We outline key histologic and immunohistochemical
features that aide in the diagnosis of LC. The presence of
cytophagocytosis on histologic examination, a phenomenon more
commonly associated with lymphoid rather than myeloid
malignancies, provided a clue to the possibility of a malignant process.
The atypical myeloid infiltrate showed S-100 protein positivity, an
unusual finding that may be seen in LC. Although not commonly
reported in LC, the presence of S-100 protein positivity and
cytophagocytosis should not lead to the premature exclusion of LC as
a possible diagnosis until a thorough clinical, histologic and
immunohistochemical evaluation is performed. In addition, the
presence of cytophagocytosis has been shown to have prognostic
significance for patients with myeloid leukemia.
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Cutaneous involvement by leukemic cells, consisting
of myeloblasts and myeloid cells in varying stages
of differentiation, is referred to as myeloid leukemia
cutis (LC).1 Most cases of myeloid LC have been
observed in patients with acute myeloid leukemia
(AML) or myeloproliferative disorders; however,
cutaneous involvement has been reported in patients
with myelodysplasia as well.2– 4 It may also present
without prior or concurrent leukemia, referred to
as ‘aleukemic leukemia cutis’.5– 7 This presentation
provides the greatest diagnostic challenge, requiring
careful histologic and cytologic evaluation for myeloid
differentiation, coupled with appropriate interpre-
tation of a carefully selected immunohistochemical
panel.
Case report
An 87-year-old woman presented with a two-week
history of erythematous papules with central crust on
her arms, legs and upper chest. She described them as
mildly pruritic and denied any prior history of similar
lesions. Her past medical history was significant for
hypothyroidism and hyperlipidemia. There was no
recent change in her medications. Clinically, an
arthropod assault or pyoderma gangrenosum was
suspected. A 4-mm punch biopsy was performed on
a representative lesion from the left anterior thigh.
The biopsy revealed a superficial atypical infiltrate
of the papillary and reticular dermis with a predom-
inantly perivascular, but somewhat interstitial distri-
bution pattern (Fig. 1A, B). A grenz zone was noted
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Fig. 1. (A) A superficial perivascular and interstitial infiltrate of
the papillary and reticular dermis was present (H&E stain, ×20
magnification). (B) Evidence of a grenz zone was noted above an
atypical superficial infiltrate (H&E stain, ×200 magnification).
above the infiltrate. Cytophagocytosis was focally
noted throughout the lesion (Fig 2A, B). The atypi-
cal cells were reactive for lysozyme, CD43, CD68,
CD117 and S-100 protein (Fig. 3). Immunohisto-
chemical stains to CD34, CD1a, myeloperoxidase,
CD79a and CD20 were nonreactive in the cells
in question. A reactive T-cell population was high-
lighted with CD3. Special stains for infectious agents,
including PAS, GMS and Gram stain, were negative
for microorganisms and fungus. Based on the histo-
logic and immunophenotypic features, a diagnosis of
myeloid LC was rendered.
Peripheral blood studies, a bone marrow biopsy,
flow cytometry and molecular studies were subse-
quently performed. The patient was found to have
a normocytic anemia (hemoglobin 11.1 g/dl; mean
corpuscular volume of 88.8 fl) and thrombocytopenia
(platelets 89 K/μl). A complete blood count revealed
an elevated white blood cell count of 22.21 K/μl with
a differential of 36% blasts, 24% neutrophils, 19%
(A)
(B)
Fig. 2. (A & B) Photomicrograph of a representative skin papule
showing atypical cells and the presence of cytophagocytosis (H&E
stain, ×400 magnification).
Fig. 3. Immunohistochemistry demonstrated expression of S-100
protein by the atypical myelomonocytic cells (S100-protein, ×400
magnification).
monocytes, 10% myelocytes, 5% metamyelocytes,
2% promyelocytes and 1% lymphocytes. The bone
marrow biopsy revealed hypercellular bone marrow
(80% cellularity) with sheets of immature, atypical and
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Fig. 4. Bone marrow evaluation demonstrated hypercellularity
with sheets of atypical, primitive myeloid cells (H&E stain, ×200
magnification).
mononuclear cells (Fig. 4). Four-color flow cytomet-
ric immunophenotypic studies revealed a population
of myeloid blasts that represented 45% of the ana-
lyzed events. Fluorescent in situ hybridization studies
for a translocation of the MLL gene on chromosome
11 were negative, and cytogenetic studies showed a
normal female karyotype. The histologic, cytogenetic
and immunophenotypic characteristics were those of
an acute myelomonocytic leukemia.
Discussion
Myeloid LC is the cutaneous involvement of leukemic
cells consisting of myeloblasts and other myeloid
precursors. Leukemic infiltration of the skin pro-
ducing a solitary lesion may also be referred to as
myeloid sarcoma or extramedullary myeloid tumor.
Other terms that have been employed in the past
include granulocytic sarcoma, chloroma, myeloblas-
toma, myelocytoma, granulocytic leukosarcoma and
chloromyeloma.6,8 The term chloroma originated
secondary to the green color occasionally seen on
gross examination, attributable to the presence of the
intracellular enzyme myeloperoxidase.9
LC has a diverse range of clinical presentations
and may present as erythematous macules, papules,
plaques, nodules or ulcerative lesions, with a
predilection for the lower extremities followed by the
upper extremities, trunk and face.6,10,11 Myeloid LC
shows a bimodal age distribution, most commonly
occurring in patients younger than 15 years of
age and between 45 and 55 years of age.8 The
incidence of cutaneous involvement occurring in
association with leukemia has been reported to be
5% to 15% in adults and up to 30% in children.11
Myeloid leukemia showing monocytic differentiation
more frequently involves the skin than other types
of myeloid leukemia.12 Leukemia patients with
a t(8;12) chromosomal translocation or numerical
abnormalities of chromosome 8, particularly trisomy
8, also appear to have an increased incidence of
cutaneous involvement.3,6,13,14 A de novo occurrence
or ‘aleukemic leukemia cutis’ has been described in
which no overt hematologic disorder is evident at
presentation.5,6 However, most patients presenting
with aleukemic leukemia cutis develop AML within
1 year.15,16
The histologic features of myeloid LC are variable,
and a high index of suspicion is usually necessary
to make the correct diagnosis. Helpful diagnostic
features are presented in Table 1. A misdiagnosis rate
of up to 75% has been reported in the literature.17
Most cases are initially given the diagnosis of non-
Hodgkin lymphoma, mycosis fungoides, metastatic
undifferentiated carcinoma, Burkitt lymphoma or
large cell lymphoma.1,16,18,19 The histologic pattern
varies depending on the density of the infiltrate.
A dense infiltrate usually presents with either a
diffuse or nodular and diffuse pattern with frequent
extension into the subcutaneous fat.20,21 In the setting
of a sparse infiltrate, the tumor cells are typically
confined to the dermis and are predominantly
perivascular or periappendageal in location.22 Most
cases show a well-demarcated grenz zone and
absence of epidermal involvement, although one
study showed single or multiple foci of intraepidermal
spread in more than one-third of cases.16 However,
extensive epidermotropism is usually not appreciated
and when present should raise the suspicion of
mycosis fungoides. Other histologic features that
may be seen in LC include the presence of single
tumor cells intercalating between collagen bundles,
Langerhans type giant cells, leukemic vasculitis and
focal necrosis.23– 27
Cytologic features evolve along a spectrum accord-
ing to the degree of maturation of the leukemic
cells: differentiated, immature or blastic. Differ-
entiated lesions are composed predominantly of
promyelocytes and mature neutrophils, whereas
immature lesions are primarily composed of promye-
locytes and myeloblasts. Blastic and immature
leukemic cell infiltrates often resemble large cell
lymphomas.1 Although the sensitivity is less than
50%, when present, eosinophilic precursors known
as eosinophilic myelocytes, characterized by their
large violaceous granules, may serve as an important
clue to the diagnosis of myeloid LC.6,17,28 Ancillary
ultrastructural studies may prove helpful if electron
dense granules are present within the tumor.29
Immunohistochemical analysis is mandatory in
the evaluation of LC. CD45 (leukocyte common
antigen) is expressed in approximately 90% of
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Table 1. Diagnostically helpful features of myeloid leukemia cutis
Evaluation of leukemia cutis (LC) Features
Gross examination • Pale green color of tissue owing to the presence of myeloperoxidase (diminished
if received in fixative).29
• Red fluorescence with exposure to UV light.6
Histology • Diffuse or nodular and diffuse dermal infiltrate.23
• Presence of grenz zone.16,20,23
• Frequent extension into the subcutaneous adipose tissue.20,21
• Perivascular and/or periappendageal distribution.22,23
• Atypical cells infiltrating between collagen fibers.23,27
• Focal necrosis, Langerhans’ type giant cells and leukemic vasculitis.24 – 26
Cytology • Presence of eosinophilic myelocytes (eosinophilic precursors with large
eosinophilic and basophilic granules) is a clue to the diagnosis.6,17,28
• Mitotic figures are usually present.2
• Varies with leukemic cell differentiation:1
◦ Differentiated: variable cell sizes, lobulated nuclei, some cells with eosinophilic
granularity.
◦ Immature: majority of cells with irregular vesicular nuclei and nucleoli.
◦ Blastic: monotonous, medium to large-sized cells with inconspicuous nuclei,
fine powdery chromatin, and scanty cytoplasm.
Immunohistochemistry • CD45 (leukocyte common antigen) positive in 90% of cases.19
• Lysozyme and CD43 are sensitive markers for myeloid LC.1,3,4,29,30
• Chloroacetate-esterase and myeloperoxidase stains also sensitive, but more
dependent on cellular differentiation.1
• CD117 (c-Kit) reactivity seen in 85% of myeloid LC.31
• CD68 may provide utility in more differentiated lesions.3,4,12
• Variable staining with Mac387, CD34 and CD56.30
Ultrastructural • Electron dense granules (most notably ellipsoidal granules) containing axial
crystals.29
cases of myeloid LC, and when positive, helps
to exclude non-hematopoietic neoplasms from the
differential diagnosis.19 Ritter et al. compared the
immunohistochemical profiles of cases of cutaneous
involvement by myeloid leukemia to cases of
peripheral T-cell lymphoma and found that CD34
and Mac 387 were specific, but relatively insensitive,
markers of LC.30 Menasce et al. examined 26 cases
of extramedullary involvement of myeloid leukemia
and found that the staining pattern varied according
to the degree of maturation of the neoplastic
cells. Chloroacetate-esterase, myeloperoxidase and
CD15 were expressed in the majority of well-
differentiated lesions and a smaller proportion of
poorly differentiated or blastic lesions. Lysozyme
and CD43 were the most sensitive markers with
expression in 25 (96%) and 26 (100%) of the
cases, respectively. The authors suggested an
immunohistochemical panel that included lysozyme,
CD43, chloroacetate-esterase and myeloperoxidase,
along with B and T lymphocyte markers (CD3
and CD79a or CD20), to confirm the diagnosis
of myeloid LC.1 Others have recommended the
addition of CD68, a marker of macrophage origin,
and CD117, a transmembrane tyrosine kinase
receptor, to this panel when myeloid LC is a
diagnostic consideration.3,4,12,31
The expression of S-100 protein in myeloid
LC, as found in our case, has been previously
reported in the literature.29 S-100 protein is a
calcium-binding protein which has been detected
in a variety of neoplastic and nonneoplastic tissues,
including central and peripheral nervous system
cells, melanocytes and Langerhans cells.23 Elliott
et al. evaluated 10 cases of myeloid sarcoma for
S-100 protein expression, five of which presented as
aleukemic leukemia cutis. The authors demonstrated
weak to strong S-100 protein immunoreactivity in six
cases (6/10).29 Kaiserling et al. studied 16 skin biopsy
specimens with leukemic infiltrates and found the
majority expressed S-100 protein. They went on to
hypothesize that this expression represented leukemic
cells that had undergone differentiation.23
Cytophagocytosis is a phenomenon of active
phagocytosis of leukocytes, erythrocytes and platelets.
In the dermatology literature, cytophagocytosis is
classically associated with the diagnosis of so-called
cytophagic histiocytic panniculitis, now regarded
as subcutaneous panniculitis-like T-cell lymphoma
(SPTCL), characterized histologically as panniculitis
with ‘bean bag cells’, i.e. large histiocytes containing
fragmented leukocytes.32 Cytophagocytosis by histi-
ocytes appears to be related to the production of
cytokines, particularly interferons and macrophage
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inflammatory protein 1α, produced by endothelial
cells, lymphocytes and macrophages themselves. The
phagocytic nature shown by blast cells in AMLs
might be explained by the ‘monocytic’ differentiation
of the cell population; this hypothesis is supported
by the increased association of this finding in AML
of the myelomonocytic and monocytic types.33 In
addition, the presence of cytophagocytosis by blast
cells in AMLs has also been shown to have prognos-
tic significance. Liso et al. evaluated bone marrow
and peripheral blood smears of 1138 cases of AML
for the presence of cytophagocytosis. One percent of
the AML cases showed cytophagocytosis, and these
patients had poor clinical outcomes, including dimin-
ished responses to therapy and shorter survival times,
in comparison to those cases without this histologic
feature.33,34 These findings suggest that the pres-
ence of cytophagocytosis may provide prognostic
relevance in addition to aiding in the diagnosis of
malignancy.
The combination of cytophagocytosis and S-100
protein reactive cells may generate the consideration
of Rosai-Dorfman disease (sinus histiocytosis with
massive lymphadenopathy) within the differential
diagnosis. Cutaneous involvement of Rosai-Dorfman
disease is characterized by foamy histiocytes, some
of which show emperipolesis, in a background of
a dense mixed infiltrate consisting of lymphocytes,
plasma cells and neutrophils. Emperipolesis differs
from cytophagocytosis in that the phagocytosed cells
are not digested by enzymes and are morphologically
well preserved within the histiocytes. In addition,
the characteristic histiocytic cells show diffuse, strong
cytoplasmic and nuclear staining for S-100 protein.
CD68 and lysozyme have been shown in a per-
centage of Rosai-Dorfman cells as well.35 However,
a pure cutaneous involvement of Rosai-Dorfman
disease is rare as most patients have evidence of sys-
temic involvement, facilitating in the differentiation
from LC.
The prognosis of patients with myeloid LC has
been shown to correlate with the initial presentation.
The overall outcome in patients with AML prior to
the development of LC does not appear adversely
impacted by a subsequent diagnosis of LC. However,
patients without AML at the time of diagnosis of
LC tend to have a worse prognosis.6 In addition,
correct initial diagnosis of LC at presentation has
been found to impact patient prognosis. Mansi et al.
found that patients diagnosed correctly at the time
of presentation and treated with AML protocols had
remissions lasting from 2 to 166 months, whereas
patients initially misdiagnosed were less likely to have
a period of remission.36
In conclusion, myeloid LC can be a difficult diag-
nosis when associated with an aleukemic presentation
and unexpected histologic and immunohistochemi-
cal findings. The diagnosis of LC is often made in
retrospect once leukemia becomes present clinically.
Careful evaluation of clinical, gross and histologic
findings along with employment of an appropri-
ate immunohistochemical panel may aide in the
correct diagnosis of LC at the time of initial pre-
sentation.
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